Literature DB >> 33372030

Comparison of Phenotypic Characteristics and Prognosis Between Black and White Patients in a Tertiary ALS Clinic.

David Brand1, Meraida Polak1, Jonathan D Glass2, Christina N Fournier2.   

Abstract

OBJECTIVE: To compare characteristics between Black and White patients with amyotrophic lateral sclerosis (ALS) in order to identify disparities and phenotypic variability.
METHODS: We performed database review for patients seen between 1997 and 2020 at the Emory ALS Center in Atlanta, Georgia. Patients with ALS were included for analyses if race was self-reported as Black or White and symptom onset was prior to January 1, 2017. Variables examined include race, age at onset, diagnostic delay, site of onset, median income, C9orf72 mutation status, feeding tube and tracheostomy status, vital capacity, Amyotrophic Lateral Sclerosis Functional Rating Scale-revised(ALSFRS-R) score, and survival time.
RESULTS: A total of 2,363 patient records were queried, and 1,298 were included in analysis; 203 self-identified as Black and 1,095 as White. Black patients had younger age at symptom onset, lower frequency of C9orf72 mutations, lower median income, longer diagnostic delay, and lower baseline ALSFRS-R and vital capacity compared to White patients. Black patients had a longer median survival than White patients; however, race was not an independent predictor of survival time when controlling for age at symptom onset, bulbar onset, and C9orf72 positivity.
CONCLUSIONS: Black patients with ALS had longer median survival compared to White patients, but race was not independently associated with survival after controlling for age, site of onset, and C9orf72 status, factors known to predict prognosis. Black patients with ALS had longer diagnostic delay and lower baseline ventilatory and functional status at first clinic visit compared to White patients, which could be suggestive of barriers to tertiary care. Further studies are needed to identify the underlying causes of ALS racial differences.
© 2020 American Academy of Neurology.

Entities:  

Year:  2020        PMID: 33372030     DOI: 10.1212/WNL.0000000000011396

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.

Authors:  Christina N Fournier
Journal:  Neurotherapeutics       Date:  2022-07-11       Impact factor: 6.088

2.  Genetic factors for survival in amyotrophic lateral sclerosis: an integrated approach combining a systematic review, pairwise and network meta-analysis.

Authors:  Wei-Ming Su; Xiao-Jing Gu; Qing-Qing Duan; Zheng Jiang; Xia Gao; Hui-Fang Shang; Yong-Ping Chen
Journal:  BMC Med       Date:  2022-06-27       Impact factor: 11.150

3.  Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis.

Authors:  Benjamin Rix Brooks; James D Berry; Malgorzata Ciepielewska; Ying Liu; Gustavo Suarez Zambrano; Jeffrey Zhang; Melissa Hagan
Journal:  EClinicalMedicine       Date:  2022-08-04

4.  Investigating the Genetic Profile of the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia (ALS-FTD) Continuum in Patients of Diverse Race, Ethnicity and Ancestry.

Authors:  Maysen Mesaros; Steven Lenz; Woobeen Lim; Jordan Brown; Luke Drury; Jennifer Roggenbuck
Journal:  Genes (Basel)       Date:  2021-12-28       Impact factor: 4.096

5.  Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis.

Authors:  Jiayu Fu; Ji He; Wei Zhao; Chuan Ren; Ping Liu; Lu Chen; Dan Li; Lu Tang; Lequn Zhou; Yixuan Zhang; Xinran Ma; Gaoqi Zhang; Nan Li; Dongsheng Fan
Journal:  J Neurol       Date:  2021-07-18       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.